Access barriers to hematopoietic stem cell transplantation and CAR T-cells in US

Area of Science:

• Hematology
• Immunology
• Health Services Research

Background:

• Cellular therapies, such as hematopoietic stem cell transplantation (HCT) and chimeric antigen receptor (CAR) T-cell therapy, have advanced significantly.
• These innovative treatments offer improved patient outcomes and broader clinical applications.

Purpose of the Study:

• To review the current landscape of cellular therapy access in the United States.
• To identify key barriers contributing to inequitable access.
• To explore potential strategies for improving access to cellular therapies.

Main Methods:

• Literature review and synthesis of current data on cellular therapy access.
• Analysis of disparities related to socioeconomic factors, healthcare infrastructure, and product-specific limitations.
• Examination of global access challenges, comparing the US to other developed and developing nations.

Main Results:

• Significant inequities in access to cellular therapies persist, influenced by socioeconomic status and healthcare system structures.
• Barriers identified are common globally, particularly in low- and middle-income countries.
• Differences in healthcare systems and funding models impact access compared to other developed nations.

Conclusions:

• Addressing cellular therapy access disparities requires multi-level interventions.
• Key strategies include expanding community-based access, innovating manufacturing processes, and increasing financial support.
• Prioritizing equity in access is essential for inclusive medical innovation as cellular therapies evolve.